Added to YB: 2024-02-15
Pitch date: 2024-02-13
COYA [bullish]
Coya Therapeutics, Inc.
-13.81%
current return
Author Info
No bio for this author
Company Info
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs).
Market Cap
$101.9M
Pitch Price
$7.17
Price Target
40.50 (+555%)
Dividend
N/A
EV/EBITDA
-3.68
P/E
-5.46
EV/Sales
18.49
Sector
Biotechnology
Category
growth
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
$COYA boosts position w/ Dr. Reddy's licensing deal for COYA 302 ALS therapy. High-profile investments relieve financial risks & expand pipeline. Enough capital to sustain thru Phase 2, expecting royalties. $40.1M cash til 2026. Einhorn & Ross back vision. Bullish revisions based on royalties, acquisition potential & drug success.
Read full article (11 min)